view original post

Denali Therapeutics Inc. (NASDAQ:DNLI)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $41.10 and last traded at $41.33, with a volume of 10856 shares trading hands. The stock had previously closed at $43.96.

Specifically, CEO Ryan J. Watts sold 18,333 shares of Denali Therapeutics stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $44.92, for a total value of $823,518.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marc Tessier-Lavigne sold 20,047 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, December 30th. The shares were sold at an average price of $45.36, for a total transaction of $909,331.92. The disclosure for this sale can be found here. Insiders sold 85,425 shares of company stock valued at $3,900,471 in the last 90 days. Company insiders own 17.00% of the company’s stock.

A number of research analysts recently issued reports on DNLI shares. Oppenheimer started coverage on shares of Denali Therapeutics in a research note on Monday, September 20th. They issued an “outperform” rating and a $85.00 price target for the company. Morgan Stanley reduced their price objective on shares of Denali Therapeutics from $99.00 to $91.00 and set an “overweight” rating for the company in a research report on Thursday. Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating and set a $49.00 price objective for the company in a research report on Friday, November 19th. Finally, Evercore ISI boosted their price objective on shares of Denali Therapeutics from $70.00 to $111.00 and gave the stock an “outperform” rating in a research report on Friday, November 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $86.75.

The firm’s 50-day moving average price is $46.99 and its two-hundred day moving average price is $52.72. The firm has a market cap of $5.08 billion, a PE ratio of 296.88 and a beta of 1.75.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, November 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.23). Denali Therapeutics had a net margin of 8.38% and a return on equity of 2.72%. The business had revenue of $5.29 million during the quarter, compared to analysts’ expectations of $30.28 million. During the same quarter last year, the company earned ($0.54) EPS. The firm’s revenue for the quarter was down 43.7% compared to the same quarter last year. On average, research analysts expect that Denali Therapeutics Inc. will post -2.21 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. UBS Asset Management Americas Inc. increased its stake in Denali Therapeutics by 1.1% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 434,734 shares of the company’s stock valued at $21,932,000 after buying an additional 4,863 shares during the period. Moors & Cabot Inc. acquired a new position in Denali Therapeutics in the 3rd quarter valued at $2,057,000. Bank of New York Mellon Corp increased its stake in Denali Therapeutics by 8.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 376,719 shares of the company’s stock valued at $19,005,000 after buying an additional 29,350 shares during the period. BNP Paribas Arbitrage SA increased its stake in Denali Therapeutics by 197.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,999 shares of the company’s stock valued at $908,000 after buying an additional 11,951 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in Denali Therapeutics in the 3rd quarter valued at $397,000. 65.90% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile (NASDAQ:DNLI)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Read More: What are momentum indicators and what do they show?

Want More Great Investing Ideas?